Kshivets_WCGIC2023.pdf

Oleg Kshivets
Oleg Kshivetsthoracic/abdominal/general surgeon & surgical oncologist at Siauliai Public Hospital

5-year survival of GCP after radical procedures significantly depended on: 1) PT “early-invasive cancer”; 2) PT N0--N12; 3) Cell Ratio Factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) GC characteristics; 9) GC cell dynamics; 10) tumor localization; 11) anthropometric data; 12) surgery type. Best diagnosis and treatment strategies for GC are: 1) screening and early detection of GC; 2) availability of experienced abdominal surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunotherapy for GCP with unfavorable prognosis.

See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/370398205
Gastric Cancer: Artificial Intelligence, Complex System Analysis and Simulation for Best Management. #5
Poster · April 2023
DOI: 10.13140/RG.2.2.32721.20324
CITATIONS
0
READ
1
2 authors, including:
Some of the authors of this publication are also working on these related projects:
prognosis of esophageal cancer cell dynamics View project
World Journal of Advanced Research and Reviews, 2021, 12(02), 246–260 View project
Oleg Kshivets
Roshal Hospital, Roshal, Moscow, Russia
104 PUBLICATIONS 55 CITATIONS
SEE PROFILE
All content following this page was uploaded by Oleg Kshivets on 29 April 2023.
The user has requested enhancement of the downloaded file.
Add your
logos here
RESULTS
INTRODUCTION
METHOD
CONCLUSIONS
CONTACT INFORMATION
O. Kshivets1, N. Urazov2
1 Roshal Hospital, Surgery Dep., Moscow, Russia
2 Omsk Cancer Center, Thoracoabdominal Surgery Dep., Omsk, Russia
Gastric Cancer: Artificial Intelligence, Complex System
Analysis and Simulation for Best Management.
#5
We examined cell ratio factors (CRF) significantly
affecting gastric cancer (EC) patients (GCP) survival.
CRF - ratio between cancer cells (CC) and blood cells
subpopulations.
We analyzed data of 799 consecutive GCP (T1-4N0-2M0) (age=57.1±9.4 years; tumor size=5.4±3.1 cm) radically
operated (R0) and monitored in 1975-2023 (m=558, f=241; total gastrectomies=173, distal gastrectomies=461;
proximal gastrectomies=165; combined gastrectomies=247 with resection of esophagus, pancreas, liver,
duodenum, diaphragm, colon transversum, splenectomy, etc; only surgery-S=624, adjuvant chemoimmunotherapy-
AT=175 (5-FU + thymalin/taktivin); T1=238, T2=220, T3=184, T4=157; N0=437, N1=109, N2=253, M0=799; G1=222,
G2=164, G3=413. Variables selected for prognosis study were input levels of 45 blood parameters, sex, age, TNMG,
cell type, tumor size. Survival curves were estimated by the Kaplan-Meier method. Differences in curves between
groups of GCP were evaluated using a log-rank test. Multivariate Cox modeling, discriminant analysis, clustering,
SEPATH, Monte Carlo, bootstrap and neural networks computing were used to determine any significant dependence.
5-year survival of GCP after radical procedures
significantly depended on: 1) PT “early-invasive
cancer”; 2) PT N0--N12; 3) Cell Ratio Factors; 4) blood
cell circuit; 5) biochemical factors; 6) hemostasis
system; 7) AT; 8) GC characteristics; 9) GC cell
dynamics; 10) tumor localization; 11) anthropometric
data; 12) surgery type. Best diagnosis and treatment
strategies for GC are: 1) screening and early detection
of GC; 2) availability of experienced abdominal
surgeons because of complexity of radical procedures;
3) aggressive en block surgery and adequate lymph
node dissection for completeness; 4) precise
prediction; 5) adjuvant chemoimmunotherapy for GCP
with unfavorable prognosis.
• Overall life span (LS) was 2128.9±2300.3 days and
cumulative 5-year survival (5YS) reached 58.4%, 10 years –
51.9%, 20 years – 39%, 30 years – 27.2%. 318 GCP lived
more than 5 years (LS=4304.5±2290.6 days), 169 GCP –
more than 10 years (LS=5919.5±2020 days). 290 GCP died
because of GC (LS=651±347.2 days). Cox modeling
displayed that G CP survival significantly depended on
CRF: healthy cells/CC, erythrocytes/CC, monocytes/CC,
phase transition (PT) in terms of synergetics
early—invasive cancer; PT N0--N12, age, G1-3, hemorrhage
time, ESS, sex, AT, prothrombin index, residual nitrogen.
Neural networks, genetic algorithm selection and bootstrap
simulation revealed relationships between 5YS and PT
early—invasive cancer (rank=1); PT N0--N12 (2); healthy
cells/CC (3), erythrocytes/CC (4), thrombocytes/CC (5),
monocytes/CC (6), segmented neutrophils/CC (7),
leucocytes/CC (8), lymphocytes/CC (9), stick
neutrophils/CC (10), eosinophils/CC (11). Correct prediction
of 5YS was 100% by neural networks computing (area
under ROC curve=1.0; error=0.0).
e-mail: okshivets@yahoo.com
http://ctsnet.org/home/okshivets
http://slideshare.net/Kshivets
http://youtube.com/user/Kshivets002
Survival Function
GCP=799; 5YS=58.4%;
10YS=52.2%; 20YS=40.3%; 30YS=27.2%.
Complete Censored
-5 0 5 10 15 20 25 30 35 40
Years after Gastrectomies
0,1
0,2
0,3
0,4
0,5
0,6
0,7
0,8
0,9
1,0
Cumulative
Proportion
Surviving
Cumulative Proportion Surviving (Kaplan-Meier)
Complete Censored
10-Year Survival of Early GCP=88.4%;
10-Year Survival of Invasive GCP=41.5%;
P=0.000 by Log Rank Test.
0 5 10 15 20 25 30 35
Years after Gastrectomies
0,3
0,4
0,5
0,6
0,7
0,8
0,9
1,0
Cumulative
Proportion
Surviv
Invasive GCP
Early GCP
Cumulative Proportion Surviving (Kaplan-Meier)
Complete Censored
10-Year survival GCP N0=69.7%;
10-Year Survival GCP N1-2=29.5%;
P=0.000 by Log Rank.
0 5 10 15 20 25 30 35 40
Years after Gastrectomies
0,0
0,1
0,2
0,3
0,4
0,5
0,6
0,7
0,8
0,9
1,0
Cumulative
Proportion
Survivi
GCP N1-2
GCP N0
Cumulative Proportion Surviving (Kaplan-Meier)
10-Year Survival GCP after AT=59.7%;
10-Year Survival after Surgery=50.6%;
P=0.032 by Log Rank Test.
Complete Censored
0 5 10 15 20 25 30
Years after Gastrectomies
0,1
0,2
0,3
0,4
0,5
0,6
0,7
0,8
Cumulative
Proportion
Survivin
only Surgery
A T
View publication stats

Recommended

Kshivets O. Synergetics and Survival of Lung Cancer Patients by
Kshivets O. Synergetics and Survival of Lung Cancer PatientsKshivets O. Synergetics and Survival of Lung Cancer Patients
Kshivets O. Synergetics and Survival of Lung Cancer PatientsOleg Kshivets
7.8K views8 slides
Construction and Validation of Prognostic Signature Model Based on Metastatic... by
Construction and Validation of Prognostic Signature Model Based on Metastatic...Construction and Validation of Prognostic Signature Model Based on Metastatic...
Construction and Validation of Prognostic Signature Model Based on Metastatic...daranisaha
4 views13 slides
NY Prostate Cancer Conference - S. Stone - Session 1: Cell cycle progression ... by
NY Prostate Cancer Conference - S. Stone - Session 1: Cell cycle progression ...NY Prostate Cancer Conference - S. Stone - Session 1: Cell cycle progression ...
NY Prostate Cancer Conference - S. Stone - Session 1: Cell cycle progression ...European School of Oncology
542 views23 slides
The Prognostic Model of Differentiation-Related Lncrna Based on Bioinformatic... by
The Prognostic Model of Differentiation-Related Lncrna Based on Bioinformatic...The Prognostic Model of Differentiation-Related Lncrna Based on Bioinformatic...
The Prognostic Model of Differentiation-Related Lncrna Based on Bioinformatic...eshaasini
3 views14 slides
Identification of the Enrichment Pathways of Catalase in Multiple Primary Tumors by
Identification of the Enrichment Pathways of Catalase in Multiple Primary TumorsIdentification of the Enrichment Pathways of Catalase in Multiple Primary Tumors
Identification of the Enrichment Pathways of Catalase in Multiple Primary Tumorsdaranisaha
4 views10 slides
Kshivets IASLC_Vienna2016 by
Kshivets IASLC_Vienna2016Kshivets IASLC_Vienna2016
Kshivets IASLC_Vienna2016Oleg Kshivets
7.6K views1 slide

More Related Content

Similar to Kshivets_WCGIC2023.pdf

Pathology NET.ppt by
Pathology NET.pptPathology NET.ppt
Pathology NET.pptNirupama kothari
108 views51 slides
Kshivets barcelona2020 by
Kshivets barcelona2020Kshivets barcelona2020
Kshivets barcelona2020Oleg Kshivets
21.8K views1 slide
A new panel of DNA methylation biomarkers for screening colorectal cancer and... by
A new panel of DNA methylation biomarkers for screening colorectal cancer and...A new panel of DNA methylation biomarkers for screening colorectal cancer and...
A new panel of DNA methylation biomarkers for screening colorectal cancer and...komalicarol
11 views7 slides
Kshivets barcelona2016 by
Kshivets barcelona2016Kshivets barcelona2016
Kshivets barcelona2016Oleg Kshivets
5.8K views1 slide
Kshivets barcelona2017 by
Kshivets barcelona2017Kshivets barcelona2017
Kshivets barcelona2017Oleg Kshivets
5.1K views1 slide
Affy by
AffyAffy
Affyarnimat
229 views34 slides

Similar to Kshivets_WCGIC2023.pdf(20)

Kshivets barcelona2020 by Oleg Kshivets
Kshivets barcelona2020Kshivets barcelona2020
Kshivets barcelona2020
Oleg Kshivets21.8K views
A new panel of DNA methylation biomarkers for screening colorectal cancer and... by komalicarol
A new panel of DNA methylation biomarkers for screening colorectal cancer and...A new panel of DNA methylation biomarkers for screening colorectal cancer and...
A new panel of DNA methylation biomarkers for screening colorectal cancer and...
komalicarol11 views
Kshivets barcelona2016 by Oleg Kshivets
Kshivets barcelona2016Kshivets barcelona2016
Kshivets barcelona2016
Oleg Kshivets5.8K views
Kshivets barcelona2017 by Oleg Kshivets
Kshivets barcelona2017Kshivets barcelona2017
Kshivets barcelona2017
Oleg Kshivets5.1K views
Affy by arnimat
AffyAffy
Affy
arnimat229 views
Affy by arnimat
AffyAffy
Affy
arnimat232 views
Kshivets lc10 ys_wjarr by Oleg Kshivets
Kshivets lc10 ys_wjarrKshivets lc10 ys_wjarr
Kshivets lc10 ys_wjarr
Oleg Kshivets5.8K views
Kshivets_IASLC_Singapore2023.pdf by Oleg Kshivets
Kshivets_IASLC_Singapore2023.pdfKshivets_IASLC_Singapore2023.pdf
Kshivets_IASLC_Singapore2023.pdf
Oleg Kshivets279 views
Role of Prostate-Specific Antigen Level and Prostate Biopsy Gleason Score in ... by asclepiuspdfs
Role of Prostate-Specific Antigen Level and Prostate Biopsy Gleason Score in ...Role of Prostate-Specific Antigen Level and Prostate Biopsy Gleason Score in ...
Role of Prostate-Specific Antigen Level and Prostate Biopsy Gleason Score in ...
asclepiuspdfs93 views
Kshivets O. Lung Cancer Surgery by Oleg Kshivets
Kshivets O. Lung Cancer SurgeryKshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer Surgery
Oleg Kshivets800 views
Zinc supplementation may reduce the risk of hepatocellular carcinoma using bi... by caijjournal
Zinc supplementation may reduce the risk of hepatocellular carcinoma using bi...Zinc supplementation may reduce the risk of hepatocellular carcinoma using bi...
Zinc supplementation may reduce the risk of hepatocellular carcinoma using bi...
caijjournal130 views
DNA Amplification is a Ubiquitous Mechanism of Oncogene Activation in Lung an... by Shryli Shreekar
DNA Amplification is a Ubiquitous Mechanism of Oncogene Activation in Lung an...DNA Amplification is a Ubiquitous Mechanism of Oncogene Activation in Lung an...
DNA Amplification is a Ubiquitous Mechanism of Oncogene Activation in Lung an...
Shryli Shreekar12 views
Real-World Treatment Patterns in Relapsed/Refractory Multiple Myeloma Patient... by Howard Friedman
Real-World Treatment Patterns in Relapsed/Refractory Multiple Myeloma Patient...Real-World Treatment Patterns in Relapsed/Refractory Multiple Myeloma Patient...
Real-World Treatment Patterns in Relapsed/Refractory Multiple Myeloma Patient...
Howard Friedman15 views
PICS: Pathway Informed Classification System for cancer analysis using gene e... by David Craft
PICS: Pathway Informed Classification System for cancer analysis using gene e...PICS: Pathway Informed Classification System for cancer analysis using gene e...
PICS: Pathway Informed Classification System for cancer analysis using gene e...
David Craft595 views

More from Oleg Kshivets

KshivetsWSCTS2023_Brazil.pdf by
KshivetsWSCTS2023_Brazil.pdfKshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdfOleg Kshivets
350 views1 slide
Kshivets_SPB_WSCTS2022Eso.pdf by
Kshivets_SPB_WSCTS2022Eso.pdfKshivets_SPB_WSCTS2022Eso.pdf
Kshivets_SPB_WSCTS2022Eso.pdfOleg Kshivets
283 views19 slides
Kshivets_SPB_WSCTS2022Lung.pdf by
Kshivets_SPB_WSCTS2022Lung.pdfKshivets_SPB_WSCTS2022Lung.pdf
Kshivets_SPB_WSCTS2022Lung.pdfOleg Kshivets
275 views19 slides
Esophageal Cancer: Precise Prediction by
Esophageal Cancer: Precise Prediction      Esophageal Cancer: Precise Prediction
Esophageal Cancer: Precise Prediction Oleg Kshivets
98 views19 slides
Survival of Lung Cancer Patients after Lobectomies was Significantly Superior... by
Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...
Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...Oleg Kshivets
78 views19 slides
Kshivets elcc2022 by
Kshivets elcc2022Kshivets elcc2022
Kshivets elcc2022Oleg Kshivets
691 views1 slide

More from Oleg Kshivets(20)

KshivetsWSCTS2023_Brazil.pdf by Oleg Kshivets
KshivetsWSCTS2023_Brazil.pdfKshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdf
Oleg Kshivets350 views
Kshivets_SPB_WSCTS2022Eso.pdf by Oleg Kshivets
Kshivets_SPB_WSCTS2022Eso.pdfKshivets_SPB_WSCTS2022Eso.pdf
Kshivets_SPB_WSCTS2022Eso.pdf
Oleg Kshivets283 views
Kshivets_SPB_WSCTS2022Lung.pdf by Oleg Kshivets
Kshivets_SPB_WSCTS2022Lung.pdfKshivets_SPB_WSCTS2022Lung.pdf
Kshivets_SPB_WSCTS2022Lung.pdf
Oleg Kshivets275 views
Esophageal Cancer: Precise Prediction by Oleg Kshivets
Esophageal Cancer: Precise Prediction      Esophageal Cancer: Precise Prediction
Esophageal Cancer: Precise Prediction
Oleg Kshivets98 views
Survival of Lung Cancer Patients after Lobectomies was Significantly Superior... by Oleg Kshivets
Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...
Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...
Oleg Kshivets78 views
Kshivets gc 10_ys_wjarr-2021-0659 by Oleg Kshivets
Kshivets gc 10_ys_wjarr-2021-0659Kshivets gc 10_ys_wjarr-2021-0659
Kshivets gc 10_ys_wjarr-2021-0659
Oleg Kshivets4.9K views
Kshivets iaslc denver2021 by Oleg Kshivets
Kshivets iaslc denver2021Kshivets iaslc denver2021
Kshivets iaslc denver2021
Oleg Kshivets3.8K views
2021 esmo world_gi_poster_kshivets by Oleg Kshivets
2021 esmo world_gi_poster_kshivets2021 esmo world_gi_poster_kshivets
2021 esmo world_gi_poster_kshivets
Oleg Kshivets8.7K views
Lung Cancer: 10-Year Survival by Oleg Kshivets
Lung Cancer: 10-Year Survival           Lung Cancer: 10-Year Survival
Lung Cancer: 10-Year Survival
Oleg Kshivets40.2K views
Combined Esophagogastrectomies: Survival Outcomes in Patients with Local Adva... by Oleg Kshivets
Combined Esophagogastrectomies: Survival Outcomes in Patients with Local Adva...Combined Esophagogastrectomies: Survival Outcomes in Patients with Local Adva...
Combined Esophagogastrectomies: Survival Outcomes in Patients with Local Adva...
Oleg Kshivets16.3K views
Kshivets iaslc singapore2020 by Oleg Kshivets
Kshivets iaslc singapore2020Kshivets iaslc singapore2020
Kshivets iaslc singapore2020
Oleg Kshivets29.6K views
Kshivets ASCO Chicago2020 by Oleg Kshivets
Kshivets ASCO Chicago2020Kshivets ASCO Chicago2020
Kshivets ASCO Chicago2020
Oleg Kshivets20.1K views
Kshivets Hong Kong Sydney2020 by Oleg Kshivets
Kshivets Hong Kong Sydney2020Kshivets Hong Kong Sydney2020
Kshivets Hong Kong Sydney2020
Oleg Kshivets27.8K views
Kshivets aats new_york2019 by Oleg Kshivets
Kshivets aats new_york2019Kshivets aats new_york2019
Kshivets aats new_york2019
Oleg Kshivets29.8K views
Kshivets IASLC 2019 by Oleg Kshivets
Kshivets IASLC 2019Kshivets IASLC 2019
Kshivets IASLC 2019
Oleg Kshivets12.1K views
Kshivets wscts2019 sofia by Oleg Kshivets
Kshivets wscts2019 sofiaKshivets wscts2019 sofia
Kshivets wscts2019 sofia
Oleg Kshivets10.9K views
Kshivets barcelona2019 by Oleg Kshivets
Kshivets barcelona2019Kshivets barcelona2019
Kshivets barcelona2019
Oleg Kshivets9.9K views

Recently uploaded

NMP-9.pptx by
NMP-9.pptxNMP-9.pptx
NMP-9.pptxSai Sailesh Kumar Goothy
28 views46 slides
Diagnosis of tumor.ppt by
Diagnosis of tumor.pptDiagnosis of tumor.ppt
Diagnosis of tumor.pptSekaran T
6 views32 slides
OVARIES.pdf by
OVARIES.pdfOVARIES.pdf
OVARIES.pdfRutvikunvar Raualji (PT)
13 views15 slides
GAS CHROMATOGRAPHY-Principle, Instrumentation Advantage and disadvantage appl... by
GAS CHROMATOGRAPHY-Principle, Instrumentation Advantage and disadvantage appl...GAS CHROMATOGRAPHY-Principle, Instrumentation Advantage and disadvantage appl...
GAS CHROMATOGRAPHY-Principle, Instrumentation Advantage and disadvantage appl...DipeshGamare
12 views23 slides
Top Ayurvedic PCD Companies in India Riding the Wave of Wellness Trends by
Top Ayurvedic PCD Companies in India Riding the Wave of Wellness TrendsTop Ayurvedic PCD Companies in India Riding the Wave of Wellness Trends
Top Ayurvedic PCD Companies in India Riding the Wave of Wellness Trendsmuskansbl01
43 views15 slides
Thrives Priority Areas: Behavioral Health by
Thrives Priority Areas: Behavioral HealthThrives Priority Areas: Behavioral Health
Thrives Priority Areas: Behavioral HealthCity of Chesapeake
77 views22 slides

Recently uploaded(20)

Diagnosis of tumor.ppt by Sekaran T
Diagnosis of tumor.pptDiagnosis of tumor.ppt
Diagnosis of tumor.ppt
Sekaran T6 views
GAS CHROMATOGRAPHY-Principle, Instrumentation Advantage and disadvantage appl... by DipeshGamare
GAS CHROMATOGRAPHY-Principle, Instrumentation Advantage and disadvantage appl...GAS CHROMATOGRAPHY-Principle, Instrumentation Advantage and disadvantage appl...
GAS CHROMATOGRAPHY-Principle, Instrumentation Advantage and disadvantage appl...
DipeshGamare12 views
Top Ayurvedic PCD Companies in India Riding the Wave of Wellness Trends by muskansbl01
Top Ayurvedic PCD Companies in India Riding the Wave of Wellness TrendsTop Ayurvedic PCD Companies in India Riding the Wave of Wellness Trends
Top Ayurvedic PCD Companies in India Riding the Wave of Wellness Trends
muskansbl0143 views
CMC(CHEMISTRY,MANUFACTURING AND CONTROL).pptx by JubinNath2
CMC(CHEMISTRY,MANUFACTURING AND CONTROL).pptxCMC(CHEMISTRY,MANUFACTURING AND CONTROL).pptx
CMC(CHEMISTRY,MANUFACTURING AND CONTROL).pptx
JubinNath28 views
3rd lecture PCR-Presentation.ppt by gayubshah
3rd lecture PCR-Presentation.ppt3rd lecture PCR-Presentation.ppt
3rd lecture PCR-Presentation.ppt
gayubshah6 views
Peptic ulcer.pdf by UVAS
Peptic ulcer.pdfPeptic ulcer.pdf
Peptic ulcer.pdf
UVAS12 views
Pulmonary Embolism for Nurses.pptx by Asraf Hussain
Pulmonary Embolism for Nurses.pptxPulmonary Embolism for Nurses.pptx
Pulmonary Embolism for Nurses.pptx
Asraf Hussain33 views
PATIENTCOUNSELLING in.pptx by skShashi1
PATIENTCOUNSELLING  in.pptxPATIENTCOUNSELLING  in.pptx
PATIENTCOUNSELLING in.pptx
skShashi126 views
24th oct Pulp Therapy In Young Permanent Teeth.pptx by ismasajjad1
24th oct Pulp Therapy In Young Permanent Teeth.pptx24th oct Pulp Therapy In Young Permanent Teeth.pptx
24th oct Pulp Therapy In Young Permanent Teeth.pptx
ismasajjad114 views
Myocardial Infarction Nursing.pptx by Asraf Hussain
Myocardial Infarction Nursing.pptxMyocardial Infarction Nursing.pptx
Myocardial Infarction Nursing.pptx
Asraf Hussain14 views
VarSeq 2.5.0: VSClinical AMP Workflow from the User Perspective by Golden Helix
VarSeq 2.5.0: VSClinical AMP Workflow from the User PerspectiveVarSeq 2.5.0: VSClinical AMP Workflow from the User Perspective
VarSeq 2.5.0: VSClinical AMP Workflow from the User Perspective
Golden Helix88 views
Explore new Frontiers in Medicine with AI.pdf by Anne Marie
Explore new Frontiers in Medicine with AI.pdfExplore new Frontiers in Medicine with AI.pdf
Explore new Frontiers in Medicine with AI.pdf
Anne Marie12 views

Kshivets_WCGIC2023.pdf

  • 1. See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/370398205 Gastric Cancer: Artificial Intelligence, Complex System Analysis and Simulation for Best Management. #5 Poster · April 2023 DOI: 10.13140/RG.2.2.32721.20324 CITATIONS 0 READ 1 2 authors, including: Some of the authors of this publication are also working on these related projects: prognosis of esophageal cancer cell dynamics View project World Journal of Advanced Research and Reviews, 2021, 12(02), 246–260 View project Oleg Kshivets Roshal Hospital, Roshal, Moscow, Russia 104 PUBLICATIONS 55 CITATIONS SEE PROFILE All content following this page was uploaded by Oleg Kshivets on 29 April 2023. The user has requested enhancement of the downloaded file.
  • 2. Add your logos here RESULTS INTRODUCTION METHOD CONCLUSIONS CONTACT INFORMATION O. Kshivets1, N. Urazov2 1 Roshal Hospital, Surgery Dep., Moscow, Russia 2 Omsk Cancer Center, Thoracoabdominal Surgery Dep., Omsk, Russia Gastric Cancer: Artificial Intelligence, Complex System Analysis and Simulation for Best Management. #5 We examined cell ratio factors (CRF) significantly affecting gastric cancer (EC) patients (GCP) survival. CRF - ratio between cancer cells (CC) and blood cells subpopulations. We analyzed data of 799 consecutive GCP (T1-4N0-2M0) (age=57.1±9.4 years; tumor size=5.4±3.1 cm) radically operated (R0) and monitored in 1975-2023 (m=558, f=241; total gastrectomies=173, distal gastrectomies=461; proximal gastrectomies=165; combined gastrectomies=247 with resection of esophagus, pancreas, liver, duodenum, diaphragm, colon transversum, splenectomy, etc; only surgery-S=624, adjuvant chemoimmunotherapy- AT=175 (5-FU + thymalin/taktivin); T1=238, T2=220, T3=184, T4=157; N0=437, N1=109, N2=253, M0=799; G1=222, G2=164, G3=413. Variables selected for prognosis study were input levels of 45 blood parameters, sex, age, TNMG, cell type, tumor size. Survival curves were estimated by the Kaplan-Meier method. Differences in curves between groups of GCP were evaluated using a log-rank test. Multivariate Cox modeling, discriminant analysis, clustering, SEPATH, Monte Carlo, bootstrap and neural networks computing were used to determine any significant dependence. 5-year survival of GCP after radical procedures significantly depended on: 1) PT “early-invasive cancer”; 2) PT N0--N12; 3) Cell Ratio Factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) GC characteristics; 9) GC cell dynamics; 10) tumor localization; 11) anthropometric data; 12) surgery type. Best diagnosis and treatment strategies for GC are: 1) screening and early detection of GC; 2) availability of experienced abdominal surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunotherapy for GCP with unfavorable prognosis. • Overall life span (LS) was 2128.9±2300.3 days and cumulative 5-year survival (5YS) reached 58.4%, 10 years – 51.9%, 20 years – 39%, 30 years – 27.2%. 318 GCP lived more than 5 years (LS=4304.5±2290.6 days), 169 GCP – more than 10 years (LS=5919.5±2020 days). 290 GCP died because of GC (LS=651±347.2 days). Cox modeling displayed that G CP survival significantly depended on CRF: healthy cells/CC, erythrocytes/CC, monocytes/CC, phase transition (PT) in terms of synergetics early—invasive cancer; PT N0--N12, age, G1-3, hemorrhage time, ESS, sex, AT, prothrombin index, residual nitrogen. Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early—invasive cancer (rank=1); PT N0--N12 (2); healthy cells/CC (3), erythrocytes/CC (4), thrombocytes/CC (5), monocytes/CC (6), segmented neutrophils/CC (7), leucocytes/CC (8), lymphocytes/CC (9), stick neutrophils/CC (10), eosinophils/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0). e-mail: okshivets@yahoo.com http://ctsnet.org/home/okshivets http://slideshare.net/Kshivets http://youtube.com/user/Kshivets002 Survival Function GCP=799; 5YS=58.4%; 10YS=52.2%; 20YS=40.3%; 30YS=27.2%. Complete Censored -5 0 5 10 15 20 25 30 35 40 Years after Gastrectomies 0,1 0,2 0,3 0,4 0,5 0,6 0,7 0,8 0,9 1,0 Cumulative Proportion Surviving Cumulative Proportion Surviving (Kaplan-Meier) Complete Censored 10-Year Survival of Early GCP=88.4%; 10-Year Survival of Invasive GCP=41.5%; P=0.000 by Log Rank Test. 0 5 10 15 20 25 30 35 Years after Gastrectomies 0,3 0,4 0,5 0,6 0,7 0,8 0,9 1,0 Cumulative Proportion Surviv Invasive GCP Early GCP Cumulative Proportion Surviving (Kaplan-Meier) Complete Censored 10-Year survival GCP N0=69.7%; 10-Year Survival GCP N1-2=29.5%; P=0.000 by Log Rank. 0 5 10 15 20 25 30 35 40 Years after Gastrectomies 0,0 0,1 0,2 0,3 0,4 0,5 0,6 0,7 0,8 0,9 1,0 Cumulative Proportion Survivi GCP N1-2 GCP N0 Cumulative Proportion Surviving (Kaplan-Meier) 10-Year Survival GCP after AT=59.7%; 10-Year Survival after Surgery=50.6%; P=0.032 by Log Rank Test. Complete Censored 0 5 10 15 20 25 30 Years after Gastrectomies 0,1 0,2 0,3 0,4 0,5 0,6 0,7 0,8 Cumulative Proportion Survivin only Surgery A T View publication stats